Biopharma Shakti shows India focusing on being biopharma hub: Biocon's Shaw
Biopharma Shakti shows India focusing on being biopharma hub: Biocon's Shaw is drawing significant interest across the industry.
After cutting debt and raising $1 billion, Biocon sharpens its biosimilars and GLP-1 play, betting on scale, regulatory reform and AI to power the next growth phase
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- The 2026 NFL scouting combine
- Waymo Begins Fully Autonomous Operations With 6th-Generation Tech
- NASA reports no significant leaks in Artemis II fueling test, eyes March 6 launch
- NFL Rumors: Insider says Travis Kelce is set for his 14th NFL season, but may leave the Kansas City Chiefs amid retirement talks
Source: Original →